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Introduction
One month prevalence rates for activity-limiting neck 
pain range from 7.5% to 14.5% in the general population 
(Hogg-Johnson et al 2008, Webb et al 2003). Neck pain 
spreading down the arm is more common than neck pain 
alone and is associated with higher levels of self-reported 
disability (Daffner et al 2003). One mechanism for neck 
pain spreading down the arm is the sensitisation of neural 
tissues (Bogduk 2009).
Evidence on the beneﬁts and harms of physiotherapy 
interventions for nerve-related neck and arm pain is needed 
(Carlesso et al 2010a, Miller et al 2010). Neural tissue 
management is one physiotherapy intervention advocated 
for nerve-related neck and arm pain (Butler 2000, Childs 
et al 2008, Elvey 1986). Neural tissue management uses 
speciﬁc positions and movements of the neck and arm to 
reduce nerve mechanosensitivity, resolve symptoms, and 
restore function (Butler 2000, Coppieters and Butler 2008, 
Elvey 1986). Physiotherapists have been advised to apply 
neural tissue management carefully to minimise the chance 
that treatment will aggravate sensitised neural tissues 
(Butler 2000, Elvey 1986, Hall and Elvey 2004).
Despite it being a recommended intervention (Childs et al 
2008), it is unclear whether a multi-session neural tissue 
management program can change the short-term natural 
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history of nerve-related neck and arm pain. Allison et al 
(2002) conducted the only randomised controlled trial that 
addressed this question. Although within-group analyses 
showed signiﬁcant changes in pain and function for the 
treatment group but not the control group, the lack of a 
between-group analysis meant that no conclusive statement 
could be made about the effects of neural tissue management 
(Boutron et al 2010). However, Gross et al (2004) conducted 
a between-group analysis on these data in their systematic 
review. Standardised mean differences favoured neural 
tissue management over no intervention for improving pain 
and function but were not statistically signiﬁcant. Low 
statistical power related to the small sample (treatment = 
17, control = 10) may explain these non-signiﬁcant results. 
A randomised controlled trial with a larger sample is 
needed to determine whether neural tissue management can 
8IBUJTBMSFBEZLOPXOPOUIJTUPQJD Neck pain 
spreading down the arm is common and disabling.
8IBUUIJTTUVEZBEET Four sessions of neural tissue 
management over two weeks increased the number of 
people who experienced substantial reductions in neck 
pain, arm pain, and self-reported activity limitations. 
Adverse events such as aggravation of pain or 
headache were typically brief, non-disabling, and were 
not associated with poorer outcomes at four weeks.
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change the short-term natural history of nerve-related neck 
and arm pain. Additionally, as with other physiotherapy 
interventions for the cervical spine, detailed information 
about adverse events related to neural tissue management is 
needed (Carlesso et al 2010a).
Thus, the research questions for this study were:
1. For patients with nerve-related neck and arm pain, 
what are the beneﬁts and harms of neural tissue 
management compared to advice to remain active in 
the short term?
2. What are the characteristics (type, frequency, onset, 
duration, severity) of any adverse events that patients 
relate to neural tissue management?
3. Does experiencing an adverse event reduce a patient’s 
chance of beneﬁtting from neural tissue management?
Method
Design
A randomised controlled trial was conducted. A detailed 
protocol has been published elsewhere (Nee et al 2011). 
Participants were randomised to receive advice to remain 
active and neural tissue management (experimental group) or 
advice to remain active only (control group). The Queensland 
Clinical Trials Centre prepared the randomisation list with 
a random number generator. Randomisation occurred 
in blocks of 12 without stratiﬁcation. Participants were 
assigned to the experimental or control group in a 2:1 ratio to 
increase the data available for a separate analysis to develop 
a model that predicts the likelihood of improvement with 
neural tissue management (Nee et al 2011). Allocation was 
concealed. Group assignments were sealed in sequentially 
numbered, opaque envelopes by a research assistant who 
was not involved in data collection. Another independent 
research assistant revealed the group assignment to each 
participant after the baseline assessment. Neural tissue 
management involved a standardised program of four 
treatments over two weeks. Outcomes were measured 
at baseline and at a follow-up four weeks later. Adverse 
events that participants related to neural tissue management 
were documented with a questionnaire administered at the 
second through fourth treatments and at follow-up. Baseline 
and follow-up data were collected at a research laboratory 
within a tertiary academic institution. The examiner who 
collected baseline and follow-up data was blinded to group 
assignments. It was not possible to blind participants or the 
physiotherapists who provided interventions.
Participants, therapists, centres
Participants were recruited from the general community 
through advertisements in local newspapers and electronic 
newsletters. Eligible participants were aged 18–60 years 
with non-traumatic neck and unilateral arm pain that 
spread below the deltoid tuberosity. Symptoms had to have 
been present for at least four weeks and preceded by a pain-
free period of four weeks or longer (de Vet et al 2002). 
Participants’ average levels of neck and arm pain during the 
previous week were recorded on separate 11-point numeric 
pain rating scales (Jensen et al 1994). The mean of these 
two scores had to be ≥ 3/10 for participants to enter the trial.
Participants’ symptoms had to be reproduced by the 
upper limb neurodynamic test for the median nerve 
(ULNT1MEDIAN) and changed by structural differentiation 
(contralateral neck sidebending or releasing wrist extension) 
(Butler 2000, Elvey 1997). This ULNT1MEDIAN response 
suggested that participants’ symptoms were at least partly 
related to increased nerve mechanosensitivity (Butler 
2000, Hall and Elvey 2004). Participants with two or more 
abnormal neurological ﬁndings (decreased strength, reﬂex, 
or sensation) at the same nerve root level (C5 to T1) were 
excluded. It has been suggested that these two enrolment 
criteria would select participants who would be considered 
appropriate candidates for neural tissue management 
(Butler 2000, Elvey 1986, Hall and Elvey 2004).
Additional exclusion criteria were: bilateral arm symptoms, 
symptoms or signs suggestive of cervical myelopathy, 
physiotherapy intervention for neck and arm pain within 
the previous six weeks, previous neck or upper limb 
surgery, and medical red ﬂags (Childs et al 2004) that 
suggested serious pathology. Self-report outcomes required 
that participants were proﬁcient in speaking and reading 
English. Consecutive participants who met all enrolment 
criteria and provided informed consent entered the trial.
Physiotherapists (n = 8) who provided neural tissue 
management had postgraduate qualiﬁcations in 
musculoskeletal physiotherapy and attended a two-hour 
training session prior to initiating the trial. Physiotherapists 
were located at eight private physiotherapy practices 
in the local metropolitan area. Participants assigned to 
the experimental group received treatment at the most 
convenient location.
Intervention
All participants were advised to continue their usual 
activities after the baseline assessment. Baseline 
medication use was documented and participants were 
allowed to continue use of over-the-counter or prescription 
medications for their symptoms as needed or as instructed 
by their medical practitioner.
Neural tissue management was based on principles proposed 
by Elvey (1986) and Butler (2000). Along with advice to 
continue their usual activities, participants assigned to the 
experimental group received an educational component, 
manual therapy techniques, and a home program of nerve 
gliding exercises. The educational component attempted to 
reduce unnecessary apprehension participants may have 
had about neural tissue management (Butler 2000). The 
manual therapy techniques and nerve gliding exercises 
have been advocated for reducing nerve mechanosensitivity 
(Butler 2000, Coppieters and Butler 2008, Elvey 1986).
The educational component emphasised two points. First, 
examination ﬁndings suggested that participants’ symptoms 
were at least partly related to nerves in the neck and arm 
that had become overly sensitive to movement. Second, 
neural tissue management techniques would move the 
nerves in a gentle and pain-free manner, aiming to reduce 
this sensitivity. The manual therapy techniques included 
a contralateral cervical lateral glide and a shoulder girdle 
oscillation combined with active craniocervical ﬂexion to 
elongate the posterior cervical spine (Elvey 1986). The home 
program of nerve gliding exercises involved a ‘sliding’ and 
a ‘tensioning’ technique for the median nerve and cervical 
nerve roots (Coppieters and Butler 2008). In the ‘sliding’ 
technique, a movement that lengthened the median nerve 
bed (elbow and wrist extension) was counterbalanced by a 
movement that shortened the nerve bed (neck lateral ﬂexion 
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or rotation toward the symptomatic arm). The ‘tensioning’ 
technique only used movements that lengthened the 
median nerve bed (elbow and wrist extension alone or 
combined with neck lateral ﬂexion or rotation away from 
the symptomatic arm). Shoulder abduction angles up to 
90 degrees were used to preload the neural tissues during 
manual therapy techniques and nerve gliding exercises. 
Neural tissue management techniques were prescribed to 
not provoke participants’ symptoms. A gentle stretching 
or pulling sensation that settled immediately after the 
technique was the maximum sensory response allowed. 
Detailed protocols for applying neural tissue management 
techniques have been described previously (Nee et al 2011).
To verify that neural tissue management did not worsen 
a participant’s condition, physiotherapists monitored the 
body diagram, the mean numeric pain rating score for 
current, highest, and lowest levels of arm pain during the 
previous 24 hours (Cleland et al 2008), and the Patient-
Speciﬁc Functional Scale (Westaway et al 1998) at the 
start of each treatment. Any indication that a participant’s 
condition may have worsened (new report of numbness 
or tingling, ≥ 1 point increase in arm pain, or ≥ 1 point 
decrease in average Patient-Speciﬁc Functional Scale 
score) required the physiotherapist to recheck strength, 
reﬂexes, and sensation to make sure the participant did 
not have two or more abnormal neurological ﬁndings. The 
physiotherapist and participant discussed and documented 
whether they felt any exacerbation was related to neural 
tissue management or to some other change in activity level. 
Neural tissue management was stopped if an exacerbation 
occurred that was associated with the development of two 
or more abnormal neurological ﬁndings. The participant 
was monitored after the follow-up assessment and referred 
for medical management as necessary. Data were retained 
for statistical analysis in accordance with intention-to-treat 
principles (Moher et al 2010).
Participants assigned to the control group received only 
advice to continue their usual activities. This provided a 
measure of the natural history of nerve-related neck and 
arm pain. To encourage these participants to remain in the 
study for the 4-week control period without treatment, they 
were advised that they would receive treatment afterwards, 
as shown in Figure 1. After the trial, they received 
four complimentary treatments from one of the trial’s 
physiotherapists. Interventions were at the physiotherapists’ 
discretion and no data were collected.
Outcome measures
The primary outcome for the beneﬁts of neural tissue 
management was participant-reported improvement on a 
15-point Global Rating of Change scale. The scale spans 
from –7 (‘a very great deal worse’) to 0 (‘no change’) to +7 
(‘a very great deal better’) (Jaeschke et al 1989). Participants 
who reported a change ≥ +4 (at least ‘moderately better’) at 
follow-up were classiﬁed as ‘improved’. This represents at 
least moderate improvement in the participant’s condition 
(Jaeschke et al 1989).
Secondary outcomes for the beneﬁts of neural tissue 
management were improvements in impairments in 
neck and arm pain intensity and reduced participant-
reported activity limitations. Neck and arm pain intensity 
were measured by mean numeric pain rating scores for 
the participant’s current, highest, and lowest levels of 
pain during the previous 24 hours (Cleland et al 2008). 
Participant-reported activity limitations were measured by 
the Neck Disability Index (Vernon and Moir 1991) and the 
Patient-Speciﬁc Functional Scale (Westaway et al 1998).
The Global Rating of Change was also the primary 
outcome for harms related to neural tissue management. 
Participants with a change ≤ –2 (at least ‘a little worse’) at 
follow-up were classiﬁed as ‘worse’. Secondary outcomes 
included the number of participants who stopped neural 
tissue management early because they developed two or 
more abnormal neurological signs during an exacerbation 
that they and the physiotherapist related to neural tissue 
management and adverse events that participants related to 
neural tissue management.
An adverse event was deﬁned as aggravation of existing 
symptoms or provocation of other unpleasant sensations 
after each neural tissue management treatment session 
(Carlesso et al 2010b, Hurwitz et al 2004). Participants 
described the characteristics (type, onset, duration, severity) 
of each adverse event on a questionnaire administered at the 
second through fourth treatments and at follow-up.
Data analysis
The difference in prevalence of ‘improvement’ (Global 
Rating of Change ≥ +4) and ‘worsening’ (Global Rating of 
Change ≤ –2) between the experimental and control groups 
were the primary analyses for the beneﬁts and harms 
of the intervention. ‘Worst case’ intention-to-treat and 
‘complete case’ analyses were performed (Moher et al 2010, 
Sterne et al 2009). In the ‘worst case’ analysis for beneﬁt, 
participants who did not return for follow-up were classiﬁed 
as ‘not improved’ if assigned to the experimental group and 
‘improved’ if assigned to control. For harm, participants 
who did not return for follow-up were classiﬁed as ‘worse’ 
if assigned to the experimental group and ‘not worse’ if 
assigned to control. ‘Complete case’ analyses included only 
participants who completed follow-up. The risk difference 
(RD) and 95% CI quantiﬁed the size of any difference in 
prevalence of improvement or worsening between the 
groups. When the 95% CI for a RD did not contain zero, 
the point estimate for the beneﬁcial or harmful effect was 
reported as a number needed to treat (NNT) or number 
needed to harm (NNH) with a 95% CI.
Differences between groups in follow-up scores for neck 
pain, arm pain, Neck Disability Index, and Patient-Speciﬁc 
Functional Scale were the secondary analyses for the 
beneﬁts of neural tissue management. Neck pain, arm pain, 
and Neck Disability Index were analysed with separate 
analyses of covariance (ANCOVA). Follow-up scores in 
each ANCOVA were adjusted by using the baseline score as 
the covariate (Vickers and Altman 2001). Because Patient-
Speciﬁc Functional Scale activities were different for each 
participant, these change scores were analysed with an 
unpaired t-test. The size of any treatment effect was reported 
as the difference between group means and a standardised 
mean difference, each with a 95% CI. The latter allowed 
a comparison to previously reported treatment effects of 
neural tissue management (Gross et al 2004). To further aid 
the interpretation of any treatment effects related to these 
secondary outcomes (Dworkin et al 2009), NNTs with 95% 
CIs were calculated for the number of participants who 
achieved clinically important change scores for neck and 
arm pain (≥ 2.2 points) (Young et al 2010), Neck Disability 
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Excluded (n = 527)
 unable to contact (n = 58)
 no clinic locations convenient (n = 41)
 age > 60 yr (n = 37)
 traumatic consent (n = 6)
 location of symptoms (n = 157)
 Yecfei_j[fW_dhWj_d]2)%'&d3*.
 physiotherapy in previous 6 wk (n = 58)
 previous neck or upper limb surgery (n = 21)
 negative median nerve neurodynamic test (n = 83)
• ≥ 2 abnormal neurological signs (n = 3)
 decided not to participate (n = 13)
 not ﬂuent in English (n = 1)
 congenital hand deformity in uninvolved limb 
prevented bilateral comparison (n = 1)
Volunteers who responded to recruitment advertisements screened for nerve-related 
neck and unilateral arm pain (n = 587)
Lost to follow-up  
(n = 2)
 changed work 
schedule prevented 
attendance at 
treatments with 
neural tissue 
management and 
participant decided 
not to attend follow-
up (n = 2)
Measured neck and arm pain intensity over previous 24 hr and participant-reported 
activity limitations with Neck Disability Index and Patient-Speciﬁc Functional Scale 
Randomised in 2:1 ratio (n = 60)
(n = 40)                                                                                             (n = 20)
Week 0
Experimental Group
 advice to remain active
 brief education
 manual therapy
 nerve gliding exercises
 4 treatments over 2 wk
Control Group
 advice to remain active Lost to follow-up (n = 2)
 no reason given 
(n = 1)
 hospitalised for 
an unrelated 
medical issue 
(n = 1)
Measured participant-reported improvement or worsening with the Global Rating of 
Change scale, neck and arm pain intensity over the previous 24 hr, and participant-
reported activity limitations with Neck Disability Index and Patient-Speciﬁc Functional 
Scale
(n = 38)                                                                                             (n = 18)
Week 4
Participation in  
study completed
Received 4 physiotherapy treatments (Physiotherapist determined intervention)
'JHVSF Design and ﬂow of participants through the trial.
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Index (≥ 7 points, 0 to 50 scale) (MacDermid et al 2009), 
and Patient-Speciﬁc Functional Scale (≥ 2.2 points) (Cleland 
et al 2006, Young et al 2010).
The characteristics of adverse events related to neural 
tissue management were reported with descriptive 
statistics. A risk ratio (RR) with a 95% CI was calculated to 
determine whether experiencing an adverse event reduced a 
participant’s chance for being improved at follow-up. Only 
‘complete case’ analyses were performed on secondary 
outcomes for the beneﬁts and harms of neural tissue 
management.
The sample size was based on having 80% power to detect a 
33% difference in the prevalence of ‘improvement’ between 
groups (p ≤ 0.05). This translates to a NNT ≤ 3, which 
was considered a clinically important treatment effect for 
changing the short-term natural history of nerve-related 
neck and arm pain. Assuming a prevalence of ‘improvement’ 
in the control group of 10% and an overall drop-out rate of 
10%, the trial required 84 participants (experimental = 56, 
control = 28).
Results
Flow of participants through the trial
Participants were recruited from July 2009 through July 
2011. Of the 587 volunteers who responded to recruitment 
advertisements, 60 entered the trial. Although the a priori 
sample size was 84, recruitment stopped at 60 because time 
constraints did not allow data collection to extend beyond 
two years. The ﬂow of participants through the trial and 
reasons for the loss to follow-up of two participants from 
the experimental group (5%) and two from the control 
group (10%) are presented in Figure 1.
Participants’ baseline characteristics are presented in Table 
1. Those in the experimental group had their symptoms 
for longer and were more likely to be using medication. 
Control group participants were slightly more likely to 
report symptoms below the elbow and that arm symptoms 
were worse than neck symptoms. There were no important 
differences between groups in baseline scores for neck 
pain, arm pain, or Neck Disability Index.
Compliance with the trial method
Follow-up visits for some participants occurred at three 
weeks rather than four, but there was no signiﬁcant 
difference in the time from baseline to follow-up between 
the experimental (mean 24 days, SD 4) and control (mean 25 
days, SD 2) groups. All participants who completed follow-
Nee et al: Neural tissue management for neck and arm pain
5BCMF Baseline characteristics of participants.
Characteristic All 
(n = 60)
Exp 
(n = 40)
Con 
(n = 20)
Gender, n female (%) 38 (63) 26 (65) 12 (60)
Age (yr), mean (SD) 47 (9) 47 (8) 48 (9)
Body Mass Index (kg/m2), mean (SD) 26.7 (4.4) 27.3 (4.7) 25.7 (3.7)
Duration of symptoms (wk), median (IQR) 26 (12 to 77) 32 (15 to 104) 18 (8 to 39)
Symptoms distal to elbow, n (%) 46 (77) 29 (73) 17 (85)
Arm symptoms worst, n (%) 20 (33) 11 (28) 9 (45)
Reported numbness or tingling, n (%) 32 (53) 20 (50) 12 (60)
Using medication for symptoms, n (%) 27 (45) 23 (58) 4 (20)
Neck pain previous 24 hrs (0 to 10), mean (SD) 4.2 (2.0) 4.3 (1.7) 4.1 (2.4)
Arm pain previous 24 hrs (0 to 10), mean (SD) 4.0 (1.6) 4.0 (1.6) 4.1 (1.6)
Neck Disability Index (0 to 50), mean (SD) 12.5 (4.4) 12.7 (4.2) 12.1 (4.7)
Exp = experimental (neural tissue management), Con = control (advice to remain active)
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'JHVSF. Distribution and frequency of Global Rating of 
Change (GROC) scores at follow-up. The bold horizontal 
line represents the median and the upper and lower 
borders of the box represent the IQR. Whiskers represent 
the largest and smallest GROC scores that would not be 
considered ‘outliers’. Dots represent individual participants 
with GROC scores that were ‘outliers’ for that group. 
Frequency of each GROC score expressed as n (%).  
Exp = experimental (neural tissue management),  
Con = control (advice to remain active).
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up received treatment as described except for one (3%) in 
the experimental group and one (5%) in the control group. 
The experimental group participant received only three 
treatments, which meant that the 38 participants in this 
group who completed follow-up received 151 treatments. 
Between treatments three and four, this participant 
experienced an exacerbation of symptoms related to an 
unusual amount of heavy lifting at work. The participant 
exhibited two abnormal neurological signs when assessed 
prior to the fourth treatment and therefore was not treated. 
The exacerbation and neurological signs were not related to 
neural tissue management in the opinion of the participant 
and physiotherapist and had resolved when the participant 
attended follow-up less than a week later. The control group 
participant attended four chiropractic treatments. Global 
Rating of Change scores indicated that neither participant 
was ‘improved’ or ‘worse’ at follow-up. These participants 
were analysed with their assigned group.
Effect of intervention
The distribution and frequency of Global Rating of 
Change scores at follow-up are presented in Figure 2. 
5BCMF ‘Worst case’ and ‘complete case’ analyses of number and proportion of participants in each group reporting a 
Global Rating of Change score classiﬁed as an ‘improvement’ or ‘worsening’.
Outcome Exp Con Risk difference 
(95% CI)
‘Improved’ at follow-up (GROC ≥!*"d%]hekfd
 ‘Worst case’ intention-to-treat analysis ('%*&+) )%(&'+ –38% 
(–16 to –60)
 ‘Complete case’ analysis ('%).++ '%'.+ –50% 
(–31 to –69)
‘Worse’ at follow-up (GROC ≤¸("d%]hekfd
 ‘Worst case’ intention-to-treat analysis +%*&') *%(&(& –7% 
(–28 to 13)
 ‘Complete case’ analysis )%).. *%'.(( –14% 
(–35 to 7)
Exp = experimental (neural tissue management), Con = control (advice to remain active), GROC = Global Rating of Change
5BCMF ‘Complete case’ analysis of mean (SD) follow-up scores for neck pain, arm pain and Neck Disability Index and 
mean (SD) change in Patient-Speciﬁc Functional Scale scores for each group, mean (95% CI) difference between groups, 
and standardised mean difference (95% CI) between groups.
Outcome Exp 
(n = 38)
Con 
(n = 18)
Difference between 
groupsa
Standardised mean 
differenceb
Neck pain previous 24 hrs (0 to 10) 2.6 (2.4) 4.2 (2.2) –2.1 
(–1.0 to –3.1)
–0.9 
(–0.5 to –1.3)
Arm pain previous 24 hrs (0 to 10) 2.4 (2.1) 4.0 (1.9) –1.5 
(–0.5 to –2.6)
–0.7 
(–0.3 to –1.1)
Neck Disability Index (0 to 50) 8.9 (5.4) 11.2 (5.0) –3.4 
(–0.6 to –6.3)
–0.6 
(–0.2 to –1.0)
Patient-Speciﬁc Functional Scalec 
change score (0 to 10)
2.0 (2.1) 0.4 (1.0) 2.1 
(0.9 to 3.2)
0.9 
(0.5 to 1.3)
a analysis of covariance (ANCOVA) with adjustment for baseline score, baseline medication use, and duration of symptoms as covariates;  
b adjusted for baseline score, baseline medication use, and duration of symptoms; c Note that because PSFS data were analysed as change 
scores, further adjustment for baseline score was not performed. Exp = experimental (neural tissue management), Con = control (advice to 
remain active)
5BCMF ‘Complete case’ analysis of number of participants (%) in each group who achieved clinically important change 
scores for impairments in pain intensity and participant-reported activity limitations, and number needed to treat (95% CI).
Outcome Exp 
(n = 38)
Con 
(n = 18)
NNT 
(95% CI)
Neck pain previous 24 hrs (0 to 10) 
(decrease ≥ 2.2 points)
13 (34) 1 (6) 3.6 
(2.1 to 10.0)
Arm pain previous 24 hrs (0 to 10) 
(decrease ≥ 2.2 points)
13 (34) 1 (6) 3.6 
(2.1 to 10.0)
Neck Disability Index (0 to 50) 
(decrease ≥ 7 points)
11 (29) 1 (6) 4.3 
(2.4 to 18.2)
Patient-Speciﬁc Functional Scale (0 to 10) 
(increase ≥ 2.2 points)
15 (39) 1 (6) 3.0 
(1.9 to 6.7)
Exp = experimental (neural tissue management), Con = control (advice to remain active), NNT = number needed to treat
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The experimental intervention changed the short-term 
natural history of nerve-related neck and arm pain. ‘Worst 
case’ intention-to-treat and ‘complete case’ analyses 
are presented in Table 2. Individual participant data are 
presented in Table 3 (see eAddenda for Table 3). These risk 
differences show that ‘improvement’ occurred signiﬁcantly 
more often among participants in the experimental group 
(Table 2). The ‘worst case’ analysis indicates that for every 
three patients treated, one more patient would achieve 
‘improvement’ than would otherwise occur (95% CI 1.7 
to 6.5). The ‘complete case’ analysis indicates that for 
every two patients treated, one more patient would achieve 
‘improvement’ than would otherwise occur (95% CI 1.5 to 
3.3). Although nearly 60% of the experimental group were 
using medication at baseline, there was no relationship 
between medication use and improvement in this group (RR 
1.02, 95% CI 0.56 to 1.84). Analyses of follow-up scores 
for pain and activity limitations added medication use and 
duration of symptoms as covariates to account for baseline 
Nee et al: Neural tissue management for neck and arm pain
differences between groups. Therefore, Patient-Speciﬁc 
Functional Scale change scores were analysed with an 
ANCOVA rather than an unpaired t-test. The experimental 
group had better follow-up scores for pain and activity 
limitations with ‘moderate’ standardised mean differences 
(≥ 0.6 but < 1.2) (Hopkins 2011) (Table 4). NNT values show 
that substantially greater proportions of participants in the 
experimental group achieved clinically important change 
scores for neck pain, arm pain, Neck Disability Index, 
and Patient-Speciﬁc Functional Scale (Table 5). Individual 
participant data for these outcomes are again presented in 
Table 3 (see eAddenda for Table 3).
There was no evidence to suggest that neural tissue 
management was harmful. ‘Worst case’ intention-to-
treat and ‘complete case’ analyses showed no difference 
in the prevalence of worsening between groups (Table 
2). Additionally, no participants had to stop neural tissue 
management early because of an exacerbation and associated 
5BCMF Characteristics of unpleasant sensations that constituted adverse events that participants related to neural tissue 
management.
Characteristic Unpleasant sensations 
(n = 82)
Participants experiencing the 
unpleasant sensation during one or 
more adverse events (n = 38)
Type, n (%)
 Aggravation of neck pain 17 (21) 14 (37)
 Aggravation of arm pain 14 (17) 12 (32)
 Aggravation of other symptomsa 5 (6) 5 (13)
 Arm weakness 9 (11) 5 (13)
 Tiredness or fatigue 11 (13) 7 (18)
 Headache 14 (17) 11 (29)
 Dizziness or imbalance 2 (2) 1 (3)
 Fainting 0 (0) 0 (0)
 Nausea or vomiting 2 (2) 1 (3)
 Blurred or impaired vision 2 (2) 2 (5)
 Tinnitus 3 (4) 2 (5)
 Confusion or disorientation 1 (1) 1 (3)
 Depression or anxiety 2 (2) 2 (5)
Time of onset after treatment, n (%)
 < 30 min 40 (49)
 30 min to 4 hr 18 (22)
 4 to 24 hr 20 (24)
 > 24 hr 4 (5)
Duration, n (%)
 < 10 min 6 (7)
 10 min to 1 hr 12 (15)
 1 to 24 hr 47 (57)
 > 24 hr 17 (21)
Intensity (0 to 10 numeric rating scale), mean (SD) 4.7 (2.1)
Restriction of home or work activities, n (%)
 None 24 (29)
 A little 48 (59)
 A lot 10 (12)
a
 numbness, tingling
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development of two or more abnormal neurological ﬁndings 
that they and the physiotherapist related to treatment.
Adverse events
Sixteen participants (42%) reported an adverse event that 
they related to neural tissue management after 29 of the 151 
treatments (19%). Questionnaires were returned for 25 of 
the 29 adverse events. The characteristics of these adverse 
events are summarised in Table 6. On average, an adverse 
event consisted of three to four unpleasant sensations (82 
unpleasant sensations over 25 adverse events). Aggravation 
of neck or arm pain and headache were most common. 
Nearly all (95%) unpleasant sensations started within 24 
hours of the previous treatment session and approximately 
80% lasted < 24 hours. Importantly, no additional 
treatments were needed for any unpleasant sensation and 
88% of unpleasant sensations had little or no impact on 
participants’ daily activities. Furthermore, experiencing 
an adverse event did not reduce a participant’s chance of 
beneﬁtting from neural tissue management because there 
was no difference in improvement rates for participants 
who did (9/16, 56%) and did not (12/22, 55%) experience an 
adverse event (RR = 1.03, 95% CI 0.58 to 1.84).
Discussion
This randomised controlled trial examined the beneﬁts 
and harms of neural tissue management as an intervention 
for nerve-related neck and arm pain. Low NNTs and 
moderate standardised mean differences show that neural 
tissue management produced clinically important beneﬁts 
for participant-reported improvement, pain intensity, and 
activity limitations at short-term follow-up when compared 
to advice to remain active. There was no evidence to 
suggest that neural tissue management was harmful. The 
prevalence of worsening was similar for the experimental 
and control groups, and no participants had to stop neural 
tissue management early because of an exacerbation that 
they and the physiotherapist related to treatment. Although 
several participants experienced adverse events that they 
related to neural tissue management, these events would be 
categorised as ‘mild’ because they did not require additional 
treatment, usually lasted < 24 hours, had minimal impact 
on daily activities, and did not reduce a participant’s chance 
of improving with neural tissue management (Carlesso et 
al 2011, Carnes et al 2010). The proportion of participants 
assigned to neural tissue management who experienced an 
adverse event and the characteristics of these events are 
similar to those reported previously for manual therapy for 
patients with neck pain (Hurwitz et al 2004). The results 
of this trial enable physiotherapists to have informed 
discussions with patients about the short-term beneﬁts and 
harms of neural tissue management for nerve-related neck 
and arm pain.
Standardised mean differences for pain were similar to 
results from the trial by Allison and colleagues (2002) (≥ 
0.7 versus 0.71), while those for activity limitations were 
larger (≥ 0.6 versus 0.34) (Gross et al 2004). The consistently 
favourable results for neural tissue management support the 
hypothesis that the lack of statistical signiﬁcance in this 
previous trial was due to the small sample.
The size and source of the sample, comparison to advice 
to remain active, and short-term follow-up are potential 
limitations of our study. Time constraints prevented 
enrolment of the a priori sample of 84 participants. Although 
we anticipated that approximately 10% of volunteers 
would enter the trial, the response to each recruitment 
advertisement was lower than expected. Enrolment stopped 
at 60 participants because data collection could not extend 
beyond two years. The concern with early stoppage of a trial 
is that any treatment effect may reﬂect a ‘random high’ in 
the data rather than the ‘true’ effect (Moher et al 2010). We 
suggest that the large beneﬁt of neural tissue management 
for participant-reported improvement in the short term 
is unlikely to be a ‘random high’ in the data because the 
‘worst case’ intention-to-treat analysis still revealed a NNT 
of three with a relatively narrow 95% CI. Clinicians should 
remember that participants were recruited from the general 
community when interpreting our results. However, we are 
unaware of any data showing that treatment effects differ 
when samples with the same enrolment criteria are recruited 
from the general community rather than the clinic.
Because advice to remain active was the control condition, 
it is unclear whether observed beneﬁts of neural tissue 
management reﬂect non-speciﬁc effects due to interacting 
with a physiotherapist or participants’ expectations, 
effects speciﬁc to neural tissue management, or to some 
combination. While discriminating non-speciﬁc from 
speciﬁc treatment effects is deemed important, establishing 
that neural tissue management can change the natural 
history of nerve-related neck and arm pain was a necessary 
prerequisite (Bialosky et al 2011). Assuming that a credible 
comparison intervention can be developed to measure 
non-speciﬁc effects accurately, future research should 
try to quantify the relative contributions that non-speciﬁc 
and speciﬁc effects make to the beneﬁts of neural tissue 
management. Future research should also determine 
whether neural tissue management provides beneﬁts in the 
longer term. Q
eAddenda: Table 3 available at jop.physiotherapy.asn.au
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